Elevar Therapeutics Receives FDA CRL for Rivoceranib-Camrelizumab HCC Combination After cGMP Site Deficiencies

A cGMP inspection failure has stalled what the FDA itself acknowledged as a clinically robust application: Elevar Therapeutics received a Complete Response Letter on July 10, 2026, for its NDA covering the rivoceranib plus camrelizumab combination as first-line therapy in unresectable or metastatic hepatocellular carcinoma. The agency cited deficiencies identified during a cGMP inspection of a manufacturing site listed on the rivoceranib NDA, not the clinical data package.

That distinction carries significant weight for QA directors and regulatory leads reviewing their own site readiness. The CARES-310 Phase 3 study underpinning the NDA reported a median overall survival of 23.8 months, the longest recorded among first-line HCC treatments to date, with consistent efficacy across subgroups and a manageable safety profile. The final analysis appeared in The Lancet Oncology in December 2025, and the regimen had already been incorporated into the 2025 Barcelona Clinic Liver Cancer treatment strategy and ESMO guidelines before U.S. approval was sought. Clinical strength, in this case, was not the limiting factor.

For manufacturing and regulatory operations teams, the CRL is a direct illustration of how site-level cGMP deficiencies can override an otherwise approvable data package. Under 21 CFR Part 211 and ICH Q10 quality system expectations, FDA pre-approval inspections assess whether a facility can reproducibly manufacture the proposed commercial product at the required quality standard. A finding sufficient to trigger a CRL typically requires a complete remediation response before the agency will reconsider the application, adding months to the approval timeline and demanding documented CAPA closure.

Elevar has stated it is reviewing the CRL contents and intends to engage with FDA promptly to determine a path forward. The company has not disclosed the specific nature of the manufacturing deficiencies, the site involved, or an estimated remediation timeline.

The outcome of Elevar's remediation response and any subsequent re-inspection will serve as a measurable indicator of how quickly a sponsor can resolve cGMP findings when clinical urgency and prior regulatory engagement are already established.

Source: GlobeNewswire via Elevar Therapeutics press release, July 10, 2026.